Patrick A. Burch

11.9k total citations · 2 hit papers
86 papers, 7.6k citations indexed

About

Patrick A. Burch is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Patrick A. Burch has authored 86 papers receiving a total of 7.6k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 18 papers in Surgery. Recurrent topics in Patrick A. Burch's work include Pancreatic and Hepatic Oncology Research (14 papers), Prostate Cancer Treatment and Research (14 papers) and Glioma Diagnosis and Treatment (8 papers). Patrick A. Burch is often cited by papers focused on Pancreatic and Hepatic Oncology Research (14 papers), Prostate Cancer Treatment and Research (14 papers) and Glioma Diagnosis and Treatment (8 papers). Patrick A. Burch collaborates with scholars based in United States, Switzerland and Japan. Patrick A. Burch's co-authors include Eric J. Small, Maha Hussain, Daniel P. Petrylak, E. David Crawford, Primo N. Lara, Mary Ellen Taplin, Catherine M. Tangen, Manish Kohli, Jeffrey A. Jones and Derek Raghavan and has published in prestigious journals such as New England Journal of Medicine, Advanced Materials and Journal of Clinical Oncology.

In The Last Decade

Patrick A. Burch

85 papers receiving 7.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

2004 2.9k citations Daniel P. Petrylak, Catherine M. Tangen et al. New England Journal of Medicine profile →
Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer

2009 605 citations Eric J. Small, Patrick A. Burch et al. Cancer profile →

Peers

Countries citing papers authored by Patrick A. Burch

Since Specialization

Citations

This map shows the geographic impact of Patrick A. Burch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick A. Burch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick A. Burch more than expected).

Fields of papers citing papers by Patrick A. Burch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick A. Burch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick A. Burch. The network helps show where Patrick A. Burch may publish in the future.

Co-authorship network of co-authors of Patrick A. Burch

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick A. Burch. A scholar is included among the top collaborators of Patrick A. Burch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick A. Burch. Patrick A. Burch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Injectable dynamic covalent hydrogels of boronic acid polymers cross-linked by bioactive plant-derived polyphenols 2018 ·Biomaterials Science ·Zhuojun Huang, Peyman Delparastan, Patrick A. Burch, Jing Cheng, Yi Cao, Phillip B. Messersmith	92
2	Biological evaluation of pyridone alkaloids on the endocannabinoid system 2017 ·Bioorganic & Medicinal Chemistry ·Andrea Chicca, Regina Berg, Henning J. Jessen, (unknown), (unknown), Patrick A. Burch, Jürg Gertsch, Karl Gademann	12
3	Obesity adversely affects survival in pancreatic cancer patients 2010 ·Cancer ·Robert R. McWilliams, Martha Matsumoto, Patrick A. Burch, George P. Kim, Þorvarður R. Hálfdánarson, Mariza de Andrade, Kaye M. Reid–Lombardo, William R. Bamlet	75
4	Phase II Study of Gemcitabine Plus Cisplatin in Patients With Metastatic Breast Cancer 2005 ·American Journal of Clinical Oncology ·Patrick A. Burch, James A. Mailliard, David W. Hillman, Edith A. Perez, James E. Krook, Kendrith M. Rowland, Michael H. Veeder, Michael W. Cannon, James N. Ingle	28
5	Serum human glandular kallikrein 2 (HK2) concentration at presentation and early subsequent follow-up for patients undergoing primary radiotherapy or brachytherapy with or without androgen deprivation therapy for localized prostate cancer therapy 2004 ·International Journal of Radiation OncologyBiologyPhysics ·Brittany E. Davis, George G. Klee, M.M. Lieber, (unknown), Marcia K. Goodmanson, Patrick A. Burch, D. J. Tindall	1
6	Serum human glandular kallikrein 2 (HK2) concentration at presentation and early subsequent follow-up for patients undergoing primary radiotherapy or brachytherapy with or without androgen deprivation therapy for localized prostate cancer therapy 2004 ·International Journal of Radiation OncologyBiologyPhysics ·Brian J. Davis, George G. Klee, Michael M. Lieber, David W. Hillman, Marcia K. Goodmanson, Patrick A. Burch, D. J. Tindall	1
7	Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer breakdown → 2004 ·New England Journal of Medicine ·Daniel P. Petrylak, Catherine M. Tangen, Maha Hussain, Primo N. Lara, Jeffrey A. Jones, Mary Ellen Taplin, Patrick A. Burch, Donna L. Berry, Carol M. Moinpour, Manish Kohli, Mitchell C. Benson, Eric J. Small, Derek Raghavan, E. David Crawford	2873
8	Birt‐Hogg–Dube Syndrome: an autosomal dominant disorder with predisposition to cancers of the kidney, fibrofolliculomas, and focal cutaneous mucinosis 2001 ·International Journal of Dermatology ·Noralane M. Lindor, Jennifer L. Hand, Patrick A. Burch, Lawrence E. Gibson	35
9	Phase II Evaluation of Continuous-Infusion 5-Fluorouracil, Leucovorin, Mitomycin-C, and Oral Dipyridamole in Advanced Measurable Pancreatic Cancer 2000 ·American Journal of Clinical Oncology ·Patrick A. Burch, (unknown), Georgene Schroeder, Cristine Allmer, (unknown), Richard M. Goldberg, (unknown), Albert M. Bernath, Loren K. Tschetter, Harold E. Windschitl, Charles D. Cobau	11
10	Results of irradiation or chemoirradiation for primary unresectable, locally recurrent, or grossly incomplete resection of gastric adenocarcinoma 2000 ·International Journal of Radiation OncologyBiologyPhysics ·G. Henning, Steven E. Schild, Scott L. Stafford, John H. Donohue, Patrick A. Burch, Michael G. Haddock, Leonard L. Gunderson	23
11	Results of irradiation or chemoirradiation following resection of gastric adenocarcinoma 2000 ·International Journal of Radiation OncologyBiologyPhysics ·G. Henning, Steven E. Schild, Scott L. Stafford, John H. Donohue, Patrick A. Burch, Michael G. Haddock, Victor F. Trastek, Leonard L. Gunderson	34
12	North Central Cancer Treatment Group Phase II Study of 5-Fluorouracil and High-Dose Levamisole for Gastric and Gastroesophageal Cancer Using Survival as the Primary Endpoint of Efficacy 1999 ·American Journal of Clinical Oncology ·Patrick A. Burch, (unknown), Georgene Schroeder, Joseph Rubin, James E. Krook, Robert J. Dalton, James B. Gerstner, (unknown), Larry P. Ebbert	3
13	Phase II North Central Cancer Treatment Group Study of 2-Chlorodeoxyadenosine in Patients With Recurrent Glioma 1999 ·American Journal of Clinical Oncology ·S. Vincent Rajkumar, Patrick A. Burch, Suresh Nair, Robert P. Dinapoli, Bernd W. Scheithauer, Judith R. OʼFallon, (unknown), (unknown), Roscoe F. Morton, Randolph S. Marks	12
14	PILOT EVALUATION OF VENLAFAXINE FOR THE TREATMENT OF HOT FLASHES IN MEN UNDERGOING ANDROGEN ABLATION THERAPY FOR PROSTATE CANCER 1999 ·The Journal of Urology ·Susan K. Quella, Charles L. Loprinzi, Jeff A. Sloan, Paul J. Novotny, Edith A. Perez, Patrick A. Burch, Stanley J. Antolak, Thomas M. Pisansky	101
15	A Phase II Study of High-Dose Cimetidine and the Combination 5-Fluorouracil, Interferon Alpha-2A, and Leucovorin in Advanced Renal Cell Adenocarcinoma 1998 ·American Journal of Clinical Oncology ·Edward T. Creagan, Michael H. Veeder, Vera J. Suman, Patrick A. Burch, William J. Maples, Paul Schaefer, Delano M. Pfeifle, Robert J. Dalton, Alan K. Hatfield, Michael A. Poon	3
16	5-Fluorouracil and Leucovorin Therapy in Patients With Hormone Refractory Prostate Cancer 1998 ·American Journal of Clinical Oncology ·Jordan Berlin, Kathleen J. Propert, Donald L. Trump, George Wilding, Gary R. Hudes, John H. Glick, Patrick A. Burch, Alan Keller, Patrick J. Loehrer	20
17	Sarcoidosis and testicular carcinoma 1998 ·Cancer ·Daniel Rayson, Patrick A. Burch, Ronald L. Richardson	73
18	Topotecan in previously treated advanced urothelial carcinoma: an ECOG phase II trial 1998 ·Investigational New Drugs ·Robert S. Witte, Judith Manola, Patrick A. Burch, Timothy M. Kuzel, (unknown), Patrick J. Loehrer	38
19	Unintentional suffocation by rebreathing: A death scene and physiologic investigation of a possible cause of sudden infant death 1993 ·The Journal of Pediatrics ·James S. Kemp, (unknown), Patrick A. Burch, Michael Graham, Bradley T. Thach	100
20	A phase II study of recombinant human alpha-interferon in advanced hormone-refractory prostate cancer 1992 ·Cancer ·(unknown), Ronald L. Richardson, John Q. Su, Jan C. Buckner, Richard G. Hahn, Stephen Frytak, Larry K. Kvols, Patrick A. Burch	17

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact